19867-34-6

Basic information

• Product Name: 6-benzyl-1-oxa-6-azaspiro[2,5]octane
• Synonyms: 6-benzyl-1-oxa-6-azaspiro[2,5]octane;6-(Phenylmethyl)-1-oxa-6-azaspiro[2.5]octane;Einecs 243-383-1
• CAS NO: 19867-34-6
• Molecular Formula: C₁₃H₁₇NO
• Molecular Weight: 203.28018
• EINECS: 243-383-1
• Mol File: 19867-34-6.mol

Chemical Properties

• Boiling Point: 302.1°Cat760mmHg
• Flash Point: 89.1°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 0.00101mmHg at 25°C
• Refractive Index: 1.586
• CAS DataBase Reference: 6-benzyl-1-oxa-6-azaspiro[2,5]octane(CAS DataBase Reference)
• NIST Chemistry Reference: 6-benzyl-1-oxa-6-azaspiro[2,5]octane(19867-34-6)
• EPA Substance Registry System: 6-benzyl-1-oxa-6-azaspiro[2,5]octane(19867-34-6)

Safety Data

• Hazardous Substances Data: 19867-34-6(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
6-Benzyl-1-oxa-6-azaspiro[2,5]octane is used as a building block for the development of new pharmaceuticals with diverse pharmacological properties. Its spiro configuration contributes to the stability and resistance to degradation, making it a promising candidate for drug design and synthesis.
Used in Drug Discovery:
6-Benzyl-1-oxa-6-azaspiro[2,5]octane is utilized in drug discovery for its potential to yield compounds with interesting biological activities. Its unique structure allows for the exploration of new therapeutic agents with novel mechanisms of action.
Used in Pharmaceutical Industry:
6-Benzyl-1-oxa-6-azaspiro[2,5]octane is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its heterocyclic nature and spiro-fused bicyclic ring system provide a versatile platform for the creation of innovative drugs with improved efficacy and safety profiles.

InChI:InChI=1/C13H17NO/c1-2-4-12(5-3-1)10-14-8-6-13(7-9-14)11-15-13/h1-5H,6-11H2

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 74-95-3 1,1-dibromomethane 
• 41979-39-9 4-piperidone hydrochloride 
• 59502-05-5 benzyl chloride-d7 
• 793-19-1 bis(2-methoxycarbonylethyl)benzylamine 
• 100-46-9 benzylamine 
• 2181-42-2 trimethylsulphonium iodide 
• 1774-47-6 trimethylsulfoxonium iodide 

Downstream Products

• 574747-38-9 N-benzyl-4-(2-fluorophenoxy)-4-hydroxymethylpiperidine 
• 574747-39-0 N-benzyl-4-(2-fluorophenoxymethyl)-4-hydroxypiperidine 
• 23804-68-4 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine 
• 92197-36-9 4-hydroxy-4-(hydroxymethyl)-1-(phenylmethyl)piperidine 
• 477721-53-2 methyl 4-[(1-benzyl-4-hydroxypiperidin-4-ylmethyl}-methylamino)benzoate 
• 1357011-81-4 1-benzyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-4-ol 
• 1357011-87-0 4-fluoro-N-[3-[4-hydroxy-4-(2-methyl-1H-benzo[d]imidazol-1-ylmethyl)-piperidin-1-yl]-1-phenylpropyl]benzamide 
• 1357011-88-1 4-fluoro-N-[3-[4-hydroxy-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-phenylpropyl]benzamide 
• 1357011-89-2 N-[3-[4-(9H-carbazol-9-ylmethyl)-4-hydroxypiperidin-1-yl]-1-phenylpropyl]-4-fluorobenzamide 
• 1357011-90-5 N-[3-[4-(1H-benzo[d][1,2,3]triazol-1-ylmethyl)-4-hydroxypiperidin-1-yl]-1-phenylpropyl]-4-fluorobenzamide 
• 1357011-91-6 N-[3-[4-(1H-benzo[d]imidazol-1-ylmethyl)-4-hydroxypiperidin-1-yl]-1-phenylpropyl]-4-fluorobenzamide 
• 1357011-92-7 4-fluoro-N-[3-[4-hydroxy-4-(1H-indol-1-ylmethyl)piperidin-1-yl]-1-phenylpropyl]benzamide 
• 1357011-93-8 N-[3-[4-hydroxy-4-(2-methyl-1H-benzo[d]imidazol-1-ylmethyl)piperidin-1-yl]-1-phenylpropyl]benzamide 
• 949100-26-9 C₁₃H₁₇N₃O 

Relevant articles and documents

Novel and efficient method to synthesize N-benzyl-4-formyl-piperidine

A novel and efficient method was developed to synthesize N-benzyl-4-formyl-piperidine, a key intermediate of Donepezil (Aricept). N-Benzyl-4-piperidone was reacted with dimethyloxosulfonium methylide to get epoxide, followed by rearrangement in the presence of magnesium bromide etherate to give target compound in high yield.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain

The synthesis and pharmacological activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivatives as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are reported. The different positions of the central scaffold, designed using a merging strategy of both target pharmacophores, were explored using a versatile synthetic approach. Phenethyl derivatives in position 9, substituted pyridyl moieties in position 4 and small alkyl groups in position 2 provided the best profiles. One of the best compounds, 15au, showed a balanced dual profile (i.e., MOR agonism and sigma antagonism) and a potent analgesic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice. Contrary to oxycodone, as expected from the addition of σ1R antagonism, 15au showed local, peripheral activity in this test, which was reversed by the σ1R agonist PRE-084. At equianalgesic doses, 15au showed less constipation than oxycodone, providing evidence that dual MOR agonism and σ1R antagonism may be a useful strategy for obtaining potent and safer analgesics.

ANTIMICROBIAL COMPOUNDS AND METHODS

The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.

Deuterated antidepressant medicine

The invention provides a compound represented by a structural formula I and a non-toxic pharmaceutically acceptable salt and use thereof in preparation of medicine for treatment of depression. In theformula I shown in the description, R1, R2, R3 and R4 are independent H or deuterium (D) separately, and meanwhile, at least one of the R1, R2, R3 and R4 must be D.

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

Continuous Flow Synthesis of Terminal Epoxides from Ketones Using in Situ Generated Bromomethyl Lithium

A scalable procedure for the direct preparation of epoxides from ketones has been developed. The method is based on the carefully controlled generation of (bromomethyl)lithium (LiCH2Br) from inexpensive CH2Br2 and MeLi in a continuous flow reactor. The reaction has shown excellent selectivity for a variety of substrates, including α-chloroketones, which typically fail under classic Corey-Chaykovsky conditions. This advantage has been used to develop a novel route toward the drug fluconazole.

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Synthesis of Functionalized 1,4-Dioxanes with an Additional (Hetero)Aliphatic Ring

An approach to the preparation of 2-mono-, 2,2- and 2,3-disubstituted 1,4-dioxane derivatives is described. The reaction sequence commences from readily available epoxides, in most cases prepared via the Corey-Chaikovsky reaction of the corresponding aldehydes and ketones. The key step of the method is epoxide ring opening with ethylene glycol monosodium salt, followed by further cyclization of the diols obtained. The utility of the approach was demonstrated by multigram preparation of novel functionalized 1,4-dioxanes bearing additional cycloalkane, piperidine or pyrrolidine rings, mostly spirocyclic compounds, which are advanced building blocks for medicinal chemistry.

N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.